Both in Biotechnology
Halozyme Therapeutics vs Exelixis
Over the past year HALO returned +94.3% and EXEL returned +90.0%; their daily moves had a correlation of 0.33.
HALO +94.3% EXEL +90.0%Growth of $1, one year, split-adjusted
| Metric | HALO | EXEL |
|---|---|---|
| Price | $128.62 | $72.31 |
| Market cap | $14.60B | $17.64B |
| Today | −0.26% | +3.11% |
| 1 month | +18.8% | +22.9% |
| 6 months | +95.3% | +62.8% |
| Year to date | +91.1% | +65.0% |
| 1 year | +97.3% | +87.0% |
| Revenue growth (YoY) | +47.7% | +10.2% |
| Gross margin | 83.5% | 96.0% |
| Net margin | 47.8% | 33.1% |
| P/E (TTM) | 35.3× | 19.9× |
| Price / sales | 8.8× | 7.1× |
| Net cash | -$1.92B | $892.0M |
| Dividend yield | — | — |
| Volatility (60d) | 27.8% | 26.8% |
| Short % of float | 12.4% | 11.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).